Pyruvate kinase M2 at a glance

Journal of Cell Science

Volumn 128, Issue 9, 2015, Pages 1655-1660

  Yang, Weiwei ^a   Lu, Zhimin ^b,c  

^a INSTITUTE OF BIOCHEMISTRY AND CELL BIOLOGY   (China)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

Gene transcription; Metabolism reprogramming; PKM2; Protein kinase; Pyruvate kinase M2

Indexed keywords

BETA CATENIN; FIBROBLAST GROWTH FACTOR RECEPTOR 1; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN; HISTONE H3; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PYRUVATE KINASE; PYRUVATE KINASE M2; REACTIVE OXYGEN METABOLITE; STAT3 PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER INHIBITION; CANCER THERAPY; CARCINOGENESIS; CELL PROLIFERATION; CELLULAR DISTRIBUTION; DNA METHYLATION; ENZYME ACTIVATION; ENZYME ACTIVITY; G1 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; GLYCOLYSIS; HISTONE ACETYLATION; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS;

ANIMALS; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PYRUVATE KINASE;

EID: 84929494270     PISSN: 00219533     EISSN: 14779137     Source Type: Journal    
DOI: 10.1242/jcs.166629     Document Type: Article

References (59)

1. Altenberg, B. and Greulich, K. O. (2004). Genes of glycolysis are ubiquitously overexpressed in 24 cancer classes. Genomics 84, 1014-1020.
2. Anastasiou, D., Poulogiannis, G., Asara, J. M., Boxer, M. B., Jiang, J. K., Shen, M., Bellinger, G., Sasaki, A. T., Locasale, J. W., Auld, D. S. et al. (2011). Inhibition of pyruvate kinase M2 by reactive oxygen species contributes to cellular antioxidant responses. Science 334, 1278-1283.
3. Anastasiou, D., Yu, Y., Israelsen, W. J., Jiang, J. K., Boxer, M. B., Hong, B. S., Tempel, W., Dimov, S., Shen, M., Jha, A. et al. (2012). Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis. Nat. Chem. Bio. 8, 839-847.
4. Bluemlein, K., Grüning, N. M., Feichtinger, R. G., Lehrach, H., Kofler, B. and Ralser, M. (2011). No evidence for a shift in pyruvate kinase PKM1 to PKM2 expression during tumorigenesis. Oncotarget 2, 393-400.
5. Chaneton, B., Hillmann, P., Zheng, L., Martin, A. C., Maddocks, O. D., Chokkathukalam, A., Coyle, J. E., Jankevics, A., Holding, F. P., Vousden, K. H. et al. (2012). Serine is a natural ligand and allosteric activator of pyruvate kinase M2. Nature 491, 458-462.
6. Chen, J., Xie, J., Jiang, Z., Wang, B., Wang, Y. and Hu, X. (2011). Shikonin and its analogs inhibit cancer cell glycolysis by targeting tumor pyruvate kinase-M2. Oncogene 30, 4297-4306.
7. Christofk, H. R., Vander Heiden, M. G., Harris, M. H., Ramanathan, A., Gerszten, R. E., Wei, R., Fleming, M. D., Schreiber, S. L. and Cantley, L. C. (2008a). The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 452, 230-233.
8. Christofk, H. R., Vander Heiden, M. G., Wu, N., Asara, J. M. and Cantley, L. C. (2008b). Pyruvate kinase M2 is a phosphotyrosine-binding protein. Nature 452, 181-186.
9. David, C. J., Chen, M., Assanah, M., Canoll, P. and Manley, J. L. (2010). HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer. Nature 463, 364-368.
10. Desai, S., Ding, M., Wang, B., Lu, Z., Zhao, Q., Shaw, K., Yung, W. K., Weinstein, J. N., Tan, M. and Yao, J. (2014). Tissue-specific isoform switch and DNA hypomethylation of the pyruvate kinase PKM gene in human cancers. Oncotarget 5, 8202-8210.
11. Discher, D. J., Bishopric, N. H., Wu, X., Peterson, C. A. and Webster, K. A. (1998). Hypoxia regulates beta-enolase and pyruvate kinase-M promoters by modulating Sp1/Sp3 binding to a conserved GC element. J. Biol. Chem. 273, 26087-26093.
12. Dombrauckas, J. D., Santarsiero, B. D. and Mesecar, A. D. (2005). Structural basis for tumor pyruvate kinase M2 allosteric regulation and catalysis. Biochemistry 44, 9417-9429.
13. Gao, X., Wang, H., Yang, J. J., Liu, X. and Liu, Z. R. (2012). Pyruvate kinase M2 regulates gene transcription by acting as a protein kinase. Mol. Cell 45, 598-609.
14. Gao, X., Wang, H., Yang, J. J., Chen, J., Jie, J., Li, L., Zhang, Y. and Liu, Z. R. (2013). Reciprocal regulation of protein kinase and pyruvate kinase activities of pyruvate kinase M2 by growth signals. J. Biol. Chem. 288, 15971-15979.
15. Gumińska, M., Stachurska, M. B. and Ignacak, J. (1988). Pyruvate kinase isoenzymes in chromatin extracts of Ehrlich ascites tumour, Morris hepatoma 7777 and normal mouse and rat livers. Biochim. Biophys. Acta 966, 207-213.
16. Guo, C., Linton, A., Jalaie, M., Kephart, S., Ornelas, M., Pairish, M., Greasley, S., Richardson, P., Maegley, K., Hickey, M. et al. (2013). Discovery of 2-((1Hbenzo[ d]imidazol-1-yl)methyl)-4H-pyrido[1,2-a]pyrimidin-4-ones as novel PKM2 activators. Bioorg. Med. Chem. Lett. 23, 3358-3363.
17. Gupta, V., Kalaiarasan, P., Faheem, M., Singh, N., Iqbal, M. A. and Bamezai, R. N. (2010). Dominant negative mutations affect oligomerization of human pyruvate kinase M2 isozyme and promote cellular growth and polyploidy. J. Biol. Chem. 285, 16864-16873.
18. Hitosugi, T., Kang, S., Vander Heiden, M. G., Chung, T. W., Elf, S., Lythgoe, K., Dong, S., Lonial, S., Wang, X., Chen, G. Z. et al. (2009). Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth. Sci. Signal. 2, ra73.
19. Iqbal, M. A., Siddiqui, F. A., Gupta, V., Chattopadhyay, S., Gopinath, P., Kumar, B., Manvati, S., Chaman, N. and Bamezai, R. N. (2013). Insulin enhances metabolic capacities of cancer cells by dual regulation of glycolytic enzyme pyruvate kinase M2. Mol. Cancer 12, 72.
20. Iqbal, M. A., Gupta, V., Gopinath, P., Mazurek, S. and Bamezai, R. N. (2014a). Pyruvate kinase M2 and cancer: an updated assessment. FEBS Lett. 588, 2685-2692.
21. Iqbal, M. A., Siddiqui, F. A., Chaman, N., Gupta, V., Kumar, B., Gopinath, P. and Bamezai, R. N. (2014b). Missense mutations in pyruvate kinase M2 promote cancer metabolism, oxidative endurance, anchorage independence, and tumor growth in a dominant negative manner. J. Biol. Chem. 289, 8098-8105.
22. Israelsen, W. J., Dayton, T. L., Davidson, S. M., Fiske, B. P., Hosios, A. M., Bellinger, G., Li, J., Yu, Y., Sasaki, M., Horner, J. W. et al. (2013). PKM2 isoform-specific deletion reveals a differential requirement for pyruvate kinase in tumor cells. Cell 155, 397-409.
23. Jiang, Y., Li, X., Yang, W., Hawke, D. H., Zheng, Y., Xia, Y., Aldape, K., Wei, C., Guo, F., Chen, Y. et al. (2014a). PKM2 regulates chromosome segregation and mitosis progression of tumor cells. Mol. Cell 53, 75-87.
24. Jiang, Y., Wang, Y., Wang, T., Hawke, D. H., Zheng, Y., Li, X., Zhou, Q., Majumder, S., Bi, E., Liu, D. X. et al. (2014b). PKM2 phosphorylates MLC2 and regulates cytokinesis of tumour cells. Nat. Commun. 5, 5566.
25. Kato, H., Fukuda, T., Parkison, C., McPhie, P. and Cheng, S. Y. (1989). Cytosolic thyroid hormone-binding protein is a monomer of pyruvate kinase. Proc. Natl. Acad. Sci. USA 86, 7861-7865.
26. Kefas, B., Comeau, L., Erdle, N., Montgomery, E., Amos, S. and Purow, B. (2010). Pyruvate kinase M2 is a target of the tumor-suppressive microRNA-326 and regulates the survival of glioma cells. Neuro-oncol. 12, 1102-1112.
27. Keller, K. E., Tan, I. S. and Lee, Y. S. (2012). SAICAR stimulates pyruvate kinase isoform M2 and promotes cancer cell survival in glucose-limited conditions. Science 338, 1069-1072.
28. Keller, K. E., Doctor, Z. M., Dwyer, Z. W. and Lee, Y. S. (2014). SAICAR induces protein kinase activity of PKM2 that is necessary for sustained proliferative signaling of cancer cells. Mol. Cell 53, 700-709.
29. Liu, A. M., Xu, Z., Shek, F. H., Wong, K. F., Lee, N. P., Poon, R. T., Chen, J. and Luk, J. M. (2014). miR-122 targets pyruvate kinase M2 and affects metabolism of hepatocellular carcinoma. PLoS ONE 9, e86872.
30. Lu, Z. (2012a). Nonmetabolic functions of pyruvate kinase isoform M2 in controlling cell cycle progression and tumorigenesis. Chin. J. Cancer 31, 5-7.
31. Lu, Z. (2012b). PKM2 functions as a histone kinase. Cell Cycle 11, 4101-4102.
32. Lu, Z. and Hunter, T. (2014). Prolyl isomerase Pin1 in cancer. Cell Res. 24, 1033-1049.
33. Lunt, S. Y., Muralidhar, V., Hosios, A. M., Israelsen, W. J., Gui, D. Y., Newhouse, L., Ogrodzinski, M., Hecht, V., Xu, K., Acevedo, P. N. et al. (2015). Pyruvate kinase isoform expression alters nucleotide synthesis to impact cell proliferation. Mol. Cell 57, 95-107.
34. Luo, W., Hu, H., Chang, R., Zhong, J., Knabel, M., O'Meally, R., Cole, R. N., Pandey, A. and Semenza, G. L. (2011). Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1. Cell 145, 732-744.
35. Lv, L., Li, D., Zhao, D., Lin, R., Chu, Y., Zhang, H., Zha, Z., Liu, Y., Li, Z., Xu, Y. et al. (2011). Acetylation targets the M2 isoform of pyruvate kinase for degradation through chaperone-mediated autophagy and promotes tumor growth. Mol. Cell 42, 719-730.
36. Lv, L., Xu, Y. P., Zhao, D., Li, F. L., Wang, W., Sasaki, N., Jiang, Y., Zhou, X., Li, T. T., Guan, K. L. et al. (2013). Mitogenic and oncogenic stimulation of K433 acetylation promotes PKM2 protein kinase activity and nuclear localization. Mol. Cell 52, 340-352.
37. Majumder, P. K., Febbo, P. G., Bikoff, R., Berger, R., Xue, Q., McMahon, L. M., Manola, J., Brugarolas, J., McDonnell, T. J., Golub, T. R. et al. (2004). mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat. Med. 10, 594-601.
38. Mellati, A. A., Yücel, M., Altinörs, N. and Gündüz, U. (1992). Regulation of M2-type pyruvate kinase from human meningioma by allosteric effectors fructose 1,6 diphosphate and L-alanine. Cancer Biochem. Biophys. 13, 33-41.
39. Morfouace, M., Lalier, L., Oliver, L., Cheray, M., Pecqueur, C., Cartron, P. F. and Vallette, F. M. (2014). Control of glioma cell death and differentiation by PKM2-Oct4 interaction. Cell Death Dis. 5, e1036.
40. Noguchi, T., Yamada, K., Inoue, H., Matsuda, T. and Tanaka, T. (1987). The L-and R-type isozymes of rat pyruvate kinase are produced from a single gene by use of different promoters. J. Biol. Chem. 262, 14366-14371.
41. Panasyuk, G., Espeillac, C., Chauvin, C., Pradelli, L. A., Horie, Y., Suzuki, A., Annicotte, J. S., Fajas, L., Foretz, M., Verdeguer, F. et al. (2012). PPARγ contributes to PKM2 and HK2 expression in fatty liver. Nat. Commun. 3, 672.
42. Porporato, P. E., Dhup, S., Dadhich, R. K., Copetti, T. and Sonveaux, P. (2011). Anticancer targets in the glycolytic metabolism of tumors: a comprehensive review. Front. Pharmacol. 2, 49.
43. Spoden, G. A., Mazurek, S., Morandell, D., Bacher, N., Ausserlechner, M. J., Jansen-Durr, P., Eigenbrodt, E. and Zwerschke, W. (2008). Isotype-specific inhibitors of the glycolytic key regulator pyruvate kinase subtype M2 moderately decelerate tumor cell proliferation. Int. J. Cancer 123, 312-321.
44. Spoden, G. A., Morandell, D., Ehehalt, D., Fiedler, M., Jansen-Dürr, P., Hermann, M. and Zwerschke, W. (2009). The SUMO-E3 ligase PIAS3 targets pyruvate kinase M2. J. Cell. Biochem. 107, 293-302.
45. Sun, Q., Chen, X., Ma, J., Peng, H., Wang, F., Zha, X., Wang, Y., Jing, Y., Yang, H., Chen, R. et al. (2011). Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth. Proc. Natl. Acad. Sci. USA 108, 4129-4134.
46. Sun, Y., Zhao, X., Zhou, Y. and Hu, Y. (2012). miR-124, miR-137 and miR-340 regulate colorectal cancer growth via inhibition of the Warburg effect. Oncol. Rep. 28, 1346-1352.
47. Vander Heiden, M. G., Christofk, H. R., Schuman, E., Subtelny, A. O., Sharfi, H., Harlow, E. E., Xian, J. and Cantley, L. C. (2010a). Identification of small molecule inhibitors of pyruvate kinase M2. Biochem. Pharmacol. 79, 1118-1124.
48. Vander Heiden, M. G., Locasale, J. W., Swanson, K. D., Sharfi, H., Heffron, G. J., Amador-Noguez, D., Christofk, H. R., Wagner, G., Rabinowitz, J. D., Asara, J. M. et al. (2010b). Evidence for an alternative glycolytic pathway in rapidly proliferating cells. Science 329, 1492-1499.
49. Wang, H. J., Hsieh, Y. J., Cheng, W. C., Lin, C. P., Lin, Y. S., Yang, S. F., Chen, C. C., Izumiya, Y., Yu, J. S., Kung, H. J. et al. (2014a). JMJD5 regulates PKM2 nuclear translocation and reprograms HIF-1α-mediated glucose metabolism. Proc. Natl. Acad. Sci. USA 111, 279-284.
50. Wang, Y. H., Israelsen, W. J., Lee, D., Yu, V. W., Jeanson, N. T., Clish, C. B., Cantley, L. C., Vander Heiden, M. G. and Scadden, D. T. (2014b). Cell-state-specific metabolic dependency in hematopoiesis and leukemogenesis. Cell 158, 1309-1323.
51. Wong, T. S., Liu, X. B., Chung-Wai Ho, A., Po-Wing Yuen, A., Wai-Man Ng, R. and Ignace Wei, W. (2008). Identification of pyruvate kinase type M2 as potential oncoprotein in squamous cell carcinoma of tongue through microRNA profiling. Int. J. Cancer 123, 251-257.
52. Xu, Y., Liu, X. H., Saunders, M., Pearce, S., Foulks, J. M., Parnell, K. M., Clifford, A., Nix, R. N., Bullough, J., Hendrickson, T. F. et al. (2014). Discovery of 3-(trifluoromethyl)-1H-pyrazole-5-carboxamide activators of the M2 isoform of pyruvate kinase (PKM2). Bioorg. Med. Chem. Lett. 24, 515-519.
53. Yamada, K., Tanaka, T., Miyamoto, K. and Noguchi, T. (2000). Sp family members and nuclear factor-Y cooperatively stimulate transcription from the rat pyruvate kinase M gene distal promoter region via their direct interactions. J. Biol. Chem. 275, 18129-18137.
54. Yang, W. and Lu, Z. (2013a). Nuclear PKM2 regulates the Warburg effect. Cell Cycle 12, 3343-3347.
55. Yang, W. and Lu, Z. (2013b). Regulation and function of pyruvate kinase M2 in cancer. Cancer Lett. 339, 153-158.
56. Yang, W., Xia, Y., Ji, H., Zheng, Y., Liang, J., Huang, W., Gao, X., Aldape, K. and Lu, Z. (2011). Nuclear PKM2 regulates beta-catenin transactivation upon EGFR activation. Nature 480, 118-122.
57. Yang, W., Xia, Y., Cao, Y., Zheng, Y., Bu, W., Zhang, L., You, M. J., Koh, M. Y., Cote, G., Aldape, K. et al. (2012a). EGFR-induced and PKCε monoubiquitylation-dependent NF-κB activation upregulates PKM2 expression and promotes tumorigenesis. Mol. Cell 48, 771-784.
58. Yang, W., Xia, Y., Hawke, D., Li, X., Liang, J., Xing, D., Aldape, K., Hunter, T., Alfred Yung, W. K. and Lu, Z. (2012b). PKM2 phosphorylates histone H3 and promotes gene transcription and tumorigenesis. Cell 150, 685-696.
59. Yang, W., Zheng, Y., Xia, Y., Ji, H., Chen, X., Guo, F., Lyssiotis, C. A., Aldape, K., Cantley, L. C. and Lu, Z. (2012c). ERK1/2-dependent phosphorylation and nuclear translocation of PKM2 promotes the Warburg effect. Nat. Cell Biol. 14, 1295-1304.